Company Analysis

Syndax Pharmaceuticals, Inc. (SNDX)

Nasdaq: SNDX · Pharmaceutical Preparations · New York, NY · filing with the SEC since 2007
Grade5.5
◀ Past 6.5● Present 4.5▶ Future 5.8
2 est.

The company now

Syndax Pharmaceuticals, Inc. is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in New York, NY. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $172 million and a loss of $285 million (its filed statements).

From its filings and filed figures; the desk's account of it is not written yet.

Where the revenue comes from

fiscal 2025, as filed

Revenue by product, fiscal 2025

ProductFiscal 2025Fiscal 2024Share of revenue
Net Product Revenues$125M$7.7M72.4%
Collaboration Revenue$42.4Mn/a24.6%
Milestone Revenue$5.1M$16.0M3.0%

As tagged in its annual report (Form 10-K, filed Feb 26, 2026 ↗), read from the SEC's financial statement data sets. The year before is the figure the record holds for the prior fiscal year.

The desk's written account of this company, its Past, Present and Future, is not on file yet.

How the company works

The desk has not read this company's annual report yet.

The record in brief

The desk has not written this company's report yet.

SI Assistanton SNDX · research, not advice